Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications

Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications

Aug 13, 2020

Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-announces-fda-filing-acceptance-xolair-omalizumab-prefilled-syringe-self-administration-across-all-indications-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-announces-fda-filing-acceptance-xolair-omalizumab-prefilled-syringe-self-administration-across-all-indications-0